Phreesia, Inc. (NYSE:PHR) Director Sells $71,572.34 in Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) Director Michael Weintraub sold 2,569 shares of Phreesia stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $27.86, for a total value of $71,572.34. Following the completion of the sale, the director now owns 143,039 shares of the company's stock, valued at approximately $3,985,066.54. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Weintraub also recently made the following trade(s):

• On Monday, June 9th, Michael Weintraub sold 7,431 shares of Phreesia stock. The shares were sold at an average price of $27.51, for a total transaction of $204,426.81.

Phreesia Stock Down 2.4%

PHR traded down $0.64 during midday trading on Friday, hitting $25.99. The company had a trading volume of 448,368 shares, compared to its average volume of 443,044. The stock's 50 day moving average price is $24.97 and its 200 day moving average price is $25.69. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -17.68 and a beta of 0.68. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The business had revenue of $115.94 million during the quarter, compared to analyst estimates of $115.00 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.05) EPS. On average, research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

A number of hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in shares of Phreesia by 10.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock worth $12,415,000 after acquiring an additional 46,209 shares during the period. Barclays PLC boosted its stake in Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company's stock worth $2,163,000 after purchasing an additional 43,225 shares during the period. Deutsche Bank AG grew its holdings in Phreesia by 95.9% during the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock valued at $1,442,000 after buying an additional 28,047 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in Phreesia during the 4th quarter valued at about $377,000. Finally, M&T Bank Corp increased its position in shares of Phreesia by 56.4% during the fourth quarter. M&T Bank Corp now owns 54,939 shares of the company's stock valued at $1,382,000 after buying an additional 19,812 shares during the period. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PHR shares. Truist Financial raised their price objective on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. DA Davidson lowered their price target on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Citigroup restated a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. Wall Street Zen upgraded shares of Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Finally, Canaccord Genuity Group dropped their price objective on Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $31.64.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.